This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Nov 12;12(11):e0006939.
doi: 10.1371/journal.pntd.0006939. eCollection 2018 Nov.

Exploring the parasite load and molecular diversity of Trypanosoma cruzi in patients with chronic Chagas disease from different regions of Brazil

Affiliations
Observational Study

Exploring the parasite load and molecular diversity of Trypanosoma cruzi in patients with chronic Chagas disease from different regions of Brazil

Ícaro Rodrigues-Dos-Santos et al. PLoS Negl Trop Dis. .

Abstract

Chagas disease is still a major public health issue in many Latin American countries. One of the current major challenges is to find an association between Trypanosoma cruzi discrete typing units (DTUs) and clinical manifestations of the disease. In this study, we used a multilocus conventional PCR and quantitative real time PCR (qPCR) approaches to perform the molecular typing and parasite load quantification directly from blood specimens of 65 chronic Chagas disease patients. All patients were recruited at the same health center, but their place of birth were widely distributed in different geographic regions of Brazil. Of the 65 patients, 35 (53.8%) presented positive amplification by real time qPCR, being 20 (30.7%) with the clinical indeterminate form and 15 (23.1%) with the cardiac form of the disease. The parasite load median for all positive patients was 2.54 [1.43-11.14] parasite equivalents/mL (par. Eq./mL), with the load ranging from 0.12 to 153.66 par. Eq./mL. Noteworthy, the parasite load was significantly higher in patients over 70 years old (median 20.05 [18.29-86.86] par. Eq./mL). Using guanidine-EDTA blood samples spiked with reference T. cruzi strains, belonging to the six DTUs, it was possible to genotype the parasite up to 0.5 par. Eq./mL, with high specificity. Of the patients with positive qPCR, it was possible to identify the T. cruzi DTU in 28 patients (80%). For the remaining patients (20%), at least a partial result was obtained. Analysis of specimens showed prevalences of TcVI, TcII and mixed infection TcVI+TcII equal to 40%, 17.1% and 14.3%, respectively. In addition, two patients were infected by TcV, and one patient was coinfected by TcIII+TcVI, These last three patients were in stage A of chronic chagasic cardiomyopathy (CCC), and they were born at the Bahia State (northeast region of Brazil). When T. cruzi genotypes were compared with the parasite load, more elevated parasite loads were observed in patients infected by TcII in general (parasite load median of 7.56 par. Eq./mL) in comparison to patients infected by TcVI (median of 2.35 par. Eq./mL). However, while the frequency of CCC was 50% in patients infected by TcVI and TcV, only 16.7% of patients infected by TcII evolved to CCC. Taking together, our results contribute to update the epidemiological knowledge of T. cruzi DTUs in Brazil, and highlight the age of patient and infection by TcII as important features that lead to the observation of higher parasitemia levels.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Parasite load in chronic patients with different clinical manifestations of Chagas disease.
In A, total parasite load (さんかく) and according the type of clinical manifestation: indeterminate (しかく) or chronic Chagas heart disease (くろまる). In B, parasite load according the severity of the cardiomyopathy: A (▼), B1 (くろまる) and C (しかく). The horizontal lines represent the median values of the parasite load.
Fig 2
Fig 2. Clinical manifestations and parasite load in chronic patients grouped by age and gender.
In A, clinical manifestations grouped by patients age and gender. Red bars: patients with cardiac form (CCC). Blue bars: patients with indeterminate form. In B, parasite load in blood of patients grouped by age and gender: Green symbols: from 30 to 49 years old; Yellow symbols: from 50 to 69 years; Brown symbols: over 70 years old. (くろまる) Male patients, (しかく) Female patients. The horizontal lines represent the parasite load median values. *P<0.05 (Mann-Whitney Rank Sum test).
Fig 3
Fig 3. Multilocus conventional PCR flowchart for T. cruzi genotyping directly from human blood samples, based on three molecular markers.
The flowchart indicates PCR product size in bp. SL-IR I and II: spliced-leader intergenic region I and II. 24Sα: heminested amplification of the D7 domain of 24Sα ribosomal RNA genes. A-10: heminested reaction for the A-10 fragment.
Fig 4
Fig 4. Multilocus conventional PCR for T. cruzi genotyping with the reference strains/clones.
PCR product sizes are indicated on the left by arrows. In A, SL-IR I and II target: Lanes—1: negative control; 2: Dm28c clone (TcI); 3: Y strain (TcII); 4: INPA 4167 strain (TcIV); 5: no template control (NTC). In B, 24Sα (second round) target: Lanes—1: NTC; 2: negative control; 3: Y strain; 4: INPA 3663 strain (TcIII); 5: Bug 2149 clone (TcV); 6: CL strain (TcVI). In C, A-10 target: 1: NTC, 2: Y strain (TcII), 3: CL strain (TcVI), 4: negative control. M- DNA ladder (100 or 50 bp).
Fig 5
Fig 5. Analytical sensitivity of multilocus conventional PCR for T. cruzi genotyping from spiked blood samples.
The PCR product sizes are indicated on the left by arrows. In A, SL-IR I and II target. In B, 24Sα (second round) target. In C, A-10 target. MW: DNA ladder (100 or 50 bp). Lanes 1–6: Dm28c clone (TcI); 7–12: Y strain (TcII); 13–18: INPA 3663 strain (TcIII); 19–24: INPA 4167 strain (TcIV); 25–30: Bug 2149 clone (TcV); 31–36: CL strain (TcVI). For all samples, Guanidine-EDTA blood was spiked with T. cruzi ranging from 104 to 0.5 par. Eq./mL (104, 103, 102, 10, 1 and 0.5 par. Eq./mL) before DNA purification.
Fig 6
Fig 6. Multilocus conventional PCR for T. cruzi genotyping from patient blood samples.
PCR product sizes (bp) are indicated on the right by arrows. In A, SL-IR I and II target. In B, 24Sα (second round) target. In C, A-10 target. Lanes 1–11: patient samples. Lane 12: no template control (NTC), Lane 13: Dm28c clone (TcI), Lane 14: Y strain (TcII), Lane 15: INPA 3663 strain (TcIII), Lane 16: CL strain (TcVI). M: 50 or 100 bp DNA ladder.
Fig 7
Fig 7. Comparison between T. cruzi genotype, clinical form and parasite load.
The symbols represent the parasite load for each patient, distributed by T. cruzi DTUs. The horizontal lines correspond to the median values of parasite load in each DTU. Red symbols indicate patients with CCC and blue symbols indicate patients with the indeterminate form.

References

    1. Coura JR, Viñas PA. Chagas disease: a new worldwide challenge. Nature. 2010; 465: S6—S7. 10.1038/nature09221 - DOI - PubMed
    1. World Health Organization (WHO). Chagas disease (American trypanosomiasis). 2015. <http://www.who.int/mediacentre/factsheets/fs340/en/>. Acessed in 06/16/2015
    1. Coura JR, Dias JC. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz. 2009; 104 Suppl 1:31–40. - PubMed
    1. Rassi Jr A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010; 375: 1388–402. 10.1016/S0140-6736(10)60061-X - DOI - PubMed
    1. Zingales B., Miles M.A., Campbell D.A., Tibayrenc M., Macedo A.M., Teixeira M.M., et al. The revised Trypanosoma cruzi subspecific nomenclature: Rationale, epidemiological relevance and research applications. Infect Genet Evol. 2012; 12(2): 240–53. 10.1016/j.meegid.201112009 - DOI - PubMed

Publication types

MeSH terms

Cite

AltStyle によって変換されたページ (->オリジナル) /